Ozempic\u00ae and Mounjaro\u00ae are the two leading injectable medications for type 2 diabetes, both approved for glycemic control and both producing substantial weight loss as a secondary effect. Ozempic (semaglutide, Novo Nordisk) was approved in 2017. Mounjaro (tirzepatide, Eli Lilly) followed in 2022.<\/p>\n
Although both are diabetes drugs by FDA indication, they’re the same molecules as Wegovy\u00ae and Zepbound\u00ae (the obesity brands at higher max doses). The difference is the label, the approved dose ceilings, and the way insurance covers them.<\/p>\n
If you’re a patient with type 2 diabetes weighing these two, the head-to-head data has become clearer over the past few years. SURPASS-2 directly compared them and Mounjaro won on both A1C and weight. But there’s nuance, especially around outcome data and access.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Ozempic contains semaglutide.<\/strong> For diabetes, it’s approved at doses of 0.25 mg (starter), 0.5 mg, 1 mg, and 2 mg per weekly injection. Semaglutide is a single agonist of the GLP-1 receptor.<\/p>\n Quick Answer: SURPASS-2 (Frias et al. 2021 NEJM) showed Mounjaro reduced A1C by 1.86% to 2.30% vs Ozempic 1 mg’s 1.86% over 40 weeks<\/p>\n Mounjaro contains tirzepatide. For diabetes, it’s approved at doses from 2.5 mg (starter) up to 15 mg per weekly injection. Tirzepatide is a dual agonist of the GLP-1 and GIP receptors.<\/p>\n Both are weekly subcutaneous injections delivered via prefilled pen.<\/p>\n Mounjaro wins on average.<\/strong> The SURPASS-2 trial (Frias et al. 2021 NEJM) directly compared Mounjaro at 5, 10, and 15 mg against Ozempic 1 mg in 1,879 adults with type 2 diabetes over 40 weeks. Mean A1C reductions were 2.01% on Mounjaro 5 mg, 2.24% on 10 mg, 2.30% on 15 mg, and 1.86% on Ozempic 1 mg.<\/p>\n The proportion of patients achieving A1C below 7% (the standard treatment target) was 85% to 90% on Mounjaro doses vs 79% on Ozempic. Achieving A1C below 5.7% (the prediabetic threshold) reached 27% to 46% on Mounjaro vs 19% on Ozempic.<\/p>\n For glycemic control, Mounjaro consistently outperforms Ozempic at comparable doses.<\/p>\n Note that since SURPASS-2, Ozempic has gained the 2 mg dose, which produces somewhat greater A1C reduction than the 1 mg tested in SURPASS-2. The gap may be smaller at maximum doses, though Mounjaro 15 mg still likely outperforms Ozempic 2 mg on average.<\/p>\n Mounjaro wins here too.<\/strong> In SURPASS-2, weight loss was 7.6 kg on Mounjaro 5 mg, 9.3 kg on 10 mg, 11.2 kg on 15 mg, and 5.7 kg on Ozempic 1 mg over 40 weeks.<\/p>\n For patients with type 2 diabetes and obesity, the higher weight loss on Mounjaro often translates to greater A1C improvement (since weight loss itself reduces insulin resistance) and better long-term metabolic outcomes.<\/p>\n Ozempic is ahead here in 2026.<\/strong> The SUSTAIN-6 trial (Marso et al. 2016 NEJM) tested semaglutide in 3,297 adults with type 2 diabetes and cardiovascular risk factors over 2.1 years. Major adverse cardiovascular events were reduced by 26%. The drug got an FDA label update reflecting this cardiovascular benefit.<\/p>\n Mounjaro’s cardiovascular outcome trial SURPASS-CVOT compares tirzepatide vs dulaglutide (another GLP-1) in adults with type 2 diabetes and cardiovascular risk. Results are expected to read out in 2025. Until then, Mounjaro doesn’t have an outcome label for cardiovascular protection in the way Ozempic does.<\/p>\n For patients with diabetes plus established cardiovascular disease, Ozempic has the stronger evidence base and the on-label CV indication.<\/p>\n Ozempic is ahead here too.<\/strong> The FLOW trial (Perkovic et al. 2024 NEJM) tested semaglutide 1 mg in 3,533 patients with type 2 diabetes and chronic kidney disease over 3.4 years. Major kidney outcomes plus cardiovascular death were reduced by 24%.<\/p>\n Mounjaro doesn’t yet have an equivalent published kidney outcome trial. For patients with diabetic kidney disease, Ozempic has the stronger published data.<\/p>\n Key Takeaway: Ozempic has SUSTAIN-6 cardiovascular outcome data showing 26% MACE reduction<\/p>\n Both have similar GI side effect profiles: nausea, vomiting, diarrhea, constipation, most common during dose escalation.<\/strong> In SURPASS-2, GI side effects on Mounjaro 15 mg were modestly more common than on Ozempic 1 mg, likely related to the higher effective dose and stronger effect. Discontinuation rates for adverse events were comparable.<\/p>\n Both have boxed warnings for medullary thyroid C-cell tumor risk based on rodent data. Both can cause gallbladder issues during rapid weight loss. Both have rare reports of pancreatitis. Both can produce modest heart rate increase and blood pressure decrease.<\/p>\n For patients who don’t tolerate one, the other is often worth trying.<\/p>\n Ozempic titrates over 8 to 16 weeks depending on target dose: 0.25 mg starter for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg (and optionally up to 2 mg after another 4+ weeks).<\/strong><\/p>\n Mounjaro titrates over 4 to 20 weeks depending on target dose: 2.5 mg starter for 4 weeks, then 5 mg, with optional further steps to 7.5, 10, 12.5, or 15 mg, each step requiring at least 4 weeks at the previous dose.<\/p>\n Mounjaro has more dose options between starter and top dose, allowing more granular titration.<\/p>\n Brand pricing in 2026: Ozempic lists at around $984\/month.<\/strong> Mounjaro lists at around $1,069\/month. Both are similar at brand list level.<\/p>\n Insurance coverage for type 2 diabetes is much broader than for obesity. Most insurance plans cover both drugs for diabetes indications with copays of $25 to $100 depending on plan. Prior authorization is typically required.<\/p>\n Manufacturer savings programs reduce out-of-pocket costs for many patients with commercial insurance. The Ozempic Savings Card can reduce copays to as low as $25\/month for eligible patients. Lilly has a similar program for Mounjaro.<\/p>\n Compounded semaglutide and tirzepatide through telehealth platforms like TrimRx run $200 to $500\/month for patients who don’t have insurance coverage or who can’t access brand drugs.<\/p>\n For patients with type 2 diabetes and a primary goal of glycemic control, both work well; Mounjaro produces stronger A1C reduction on average.<\/strong> For patients with diabetes plus established cardiovascular disease, Ozempic has the stronger CV outcome data and FDA-approved CV indication. For patients with diabetic kidney disease, Ozempic has FLOW trial data.<\/p>\n For patients with type 2 diabetes plus obesity who want stronger weight loss, Mounjaro is typically the higher-performing choice. For patients who tried one and didn’t tolerate it or didn’t respond well, the other is worth trying given the different mechanism.<\/p>\n Insurance coverage, prior authorization requirements, and personal response often determine the actual choice as much as the comparative data.<\/p>\n Bottom line: Both drugs cost around $900 to $1,000\/month at brand list price; coverage and copays vary<\/p>\n The molecules are the same (semaglutide in Ozempic\/Wegovy; tirzepatide in Mounjaro\/Zepbound), but the FDA approvals and labeled doses differ. Ozempic is approved for diabetes up to 2 mg; Wegovy is approved for obesity at 2.4 mg. Mounjaro and Zepbound have the same dose range for their respective indications.<\/p>\n Off-label prescribing for weight loss in non-diabetic patients does happen, though it’s increasingly uncommon now that Wegovy and Zepbound exist for the obesity indication. Insurance won’t cover Ozempic or Mounjaro for non-diabetic weight loss in most cases.<\/p>\n Yes, switching is common when A1C targets aren’t met on Ozempic or when stronger weight loss is desired. Most clinicians stop Ozempic and start Mounjaro at 2.5 mg or 5 mg, then titrate based on tolerance and response.<\/p>\n In patients on Mounjaro alone (monotherapy or with metformin), hypoglycemia risk is very low because both Ozempic and Mounjaro stimulate insulin only when glucose is high. The risk increases when combined with insulin or sulfonylureas, which may need dose reduction.<\/p>\n Both are covered by Medicare Part D for type 2 diabetes when prescribed for glycemic control. Medicare doesn’t cover GLP-1s for obesity in 2026, so Wegovy and Zepbound aren’t covered for that indication. Coverage rules and copays vary by plan.<\/p>\n A1C reduction typically becomes meaningful within 4 to 8 weeks. Peak A1C effect is usually reached by 12 to 16 weeks. Weight loss typically becomes visible within 4 to 8 weeks and continues building for 6 to 12 months.<\/p>\n The GI side effect profiles are similar. SURPASS-2 head-to-head showed comparable discontinuation rates. Individual tolerability varies more than the average difference between the drugs. Patients who tolerate one well often tolerate the other; patients who struggle with one sometimes do better on the other.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Introduction Ozempic\u00ae and Mounjaro\u00ae are the two leading injectable medications for type 2 diabetes, both approved for glycemic control and both producing substantial weight…<\/p>\n","protected":false},"author":11,"featured_media":93228,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Ozempic vs Mounjaro: Diabetes Drug Comparison","_yoast_wpseo_metadesc":"Ozempic\u00ae and Mounjaro\u00ae are the two leading injectable medications for type 2 diabetes, both approved for glycemic control and both producing...","_yoast_wpseo_focuskw":"ozempic mounjaro","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[21,24,35,39],"class_list":["post-90401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic","tag-comparisons","tag-diabetes","tag-mounjaro","tag-ozempic"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90401"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90401\/revisions"}],"predecessor-version":[{"id":91752,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90401\/revisions\/91752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93228"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Do They Compare on A1C Reduction?<\/h2>\n
How Do They Compare on Weight Loss?<\/h2>\n
What About Cardiovascular Outcomes?<\/h2>\n
What About Kidney Outcomes?<\/h2>\n
Side Effect Profile<\/h2>\n
How Do They Titrate?<\/h2>\n
What Does Each Cost?<\/h2>\n
Which Is Right for You?<\/h2>\n
FAQ<\/h2>\n
Are Ozempic and Mounjaro the Same as Wegovy and Zepbound?<\/h3>\n
Can I Take Ozempic or Mounjaro for Weight Loss If I Don’t Have Diabetes?<\/h3>\n
Can I Switch From Ozempic to Mounjaro?<\/h3>\n
Does Mounjaro Cause More Hypoglycemia?<\/h3>\n
Are Ozempic and Mounjaro Covered by Medicare?<\/h3>\n
How Long Until I See Results on Ozempic or Mounjaro?<\/h3>\n
Which Has Fewer Side Effects?<\/h3>\n